Literature DB >> 2460988

Treatment of painful prostatic bone metastases with oral etidronate disodium.

P O Carey1, M C Lippert.   

Abstract

A class of drugs called diphosphonates have been used for several years in benign disorders of ossification such as Paget disease. Recently, these compounds have been applied to treating hypercalcemia of malignancy and painful bone metastases. We have used one of the oral diphosphonates, etidronate disodium, to palliate pain in 12 patients suffering from multiple bone metastases from prostate cancer. All of the patients had progressive metastatic disease following earlier endocrine therapy. Ten of 12 (83%) patients had a positive subjective and clinical response to treatment with oral etidronate disodium. Daily narcotic usage and pain intensity (measured by a zero to 10 pain scale) both decreased significantly on the etidronate protocol. There were no side effects associated with the drug in our patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460988     DOI: 10.1016/0090-4295(88)90410-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

Review 1.  Targeted radionuclide therapy for bone metastases.

Authors:  V J Lewington
Journal:  Eur J Nucl Med       Date:  1993-01

Review 2.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 3.  Strategies for management of prostate cancer-related bone pain.

Authors:  R C Pelger; V Soerdjbalie-Maikoe; N A Hamdy
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 4.  Bisphosphonates for advanced prostate cancer.

Authors:  Sascha Macherey; Ina Monsef; Franziska Jahn; Karin Jordan; Kwok Keung Yuen; Axel Heidenreich; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2017-12-26

Review 5.  The role of bisphosphonates in hormone-refractory prostate cancer.

Authors:  Fred Saad; Pierre Karakiewicz; Paul Perrotte
Journal:  World J Urol       Date:  2005-01-22       Impact factor: 4.226

Review 6.  The role of bisphosphonates in the management of metastatic prostate cancer.

Authors:  M Dror Michaelson; Matthew R Smith
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

7.  [Pharmacotherapy of cancer pain. 3. Adjuvant drugs.].

Authors:  N I Cherny; R K Portenoy; M Raber; M Zenz
Journal:  Schmerz       Date:  1995-03       Impact factor: 1.107

8.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer.

Authors:  P Garnero; N Buchs; J Zekri; R Rizzoli; R E Coleman; P D Delmas
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.